DRUG Overview

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Wall Street analysts forecast DRUG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRUG is121.00 USD with a low forecast of 80.00 USD and a high forecast of 147.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bright Minds Biosciences Inc revenue for the last quarter amounts to -6.90M USD, increased 326.25

Bright Minds Biosciences Inc. EPS for the last quarter amounts to USD, decreased

Bright Minds Biosciences Inc (DRUG) has 0 emplpoyees as of March 12 2026.

Today DRUG has the market capitalization of 742.16M USD.